Dr Reddy's Laboratories announced today that Dr Daniel Rader from University of Pennsylvania in Philadelphia has joined the company’s Scientific and Clinical Advisory Board.

Dr Rader is a faculty in the Department of Medicine and the director of Cardiovascular Metabolism unit at the Institute for Diabetes, Obesity and Metabolism. He is a global thought leader in the areas of dyslipidemia and cardiovascular disease. He is a scientist with an outstanding clinical and research track record in novel therapies to raise HDL and reverse heart disease.

Dr Uday Saxena, chief scientific officer, Dr Reddy's, said, "We are delighted with Dr Rader's addition to the advisory board. He brings world-class experience and knowledge, which will help us in the clinical development of DRF 10945, our drug candidate in clinical trials for HDL elevation/ triglyceride lowering and RUS 3108, currently in Phase-I clinical trials for treatment of heart disease. In addition, his research expertise will help our other emerging drug discovery programmes in areas of diabetes, obesity and cardiovascular disease."